Product Added to Cart!
$41.30

FREE
SHIPPING

100% MONEY
BACK GUARANTEE

ONLINE
SUPPORT 24/7

Available on backorder. No lead time available. Please request a quote.
Sku CI03502_5_G
Chem Impex
Get Bulk Quote

Product Information

Product Name
Fmoc-L-citrulline
Brand Name
Chem Impex
Product Number
03502
CAS
133174-15-9
Certificate of Analysis (COA)​
COA not found

General Information

PubChem CID
2756127
IUPAC Name
(2S)-5-(carbamoylamino)-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoic acid
InChI Key
NBMSMZSRTIOFOK-SFHVURJKSA-N
SMILES
C1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)NC@@H(CCCNC(=O)N)C(=O)O

Description

Fmoc-L-citrulline is widely utilized in research focused on:

Peptide Synthesis: This compound is a key building block in the synthesis of peptides, particularly in solid-phase peptide synthesis (SPPS), allowing for the efficient assembly of complex peptide chains.

Drug Development: Its unique properties make it valuable in the development of pharmaceuticals, especially in creating peptide-based drugs that can target specific biological pathways.

Bioconjugation: Fmoc-L-citrulline can be used to modify biomolecules, enhancing their stability and functionality in various applications, including targeted drug delivery systems.

Research in Cardiovascular Health: Studies have shown that citrulline plays a role in nitric oxide production, making it relevant in research aimed at improving cardiovascular function and addressing conditions like hypertension.

Cosmetic Formulations: Its potential benefits in skin health have led to its inclusion in cosmetic products, where it may promote hydration and improve skin elasticity.

References Data Source From Pubchem

Process Optimization for the Synthesis of Enzyme-Cleavable Val-Cit Dipeptide Linker in Antibody–Drug Conjugate Production

Publication Name: Russian Journal of Organic Chemistry
Publication Date: 2025-12
DOI: 10.1134/s1070428025601670

Symplocamide A as marine-derived proteasome inhibitor: a promising scaffold for targeted cancer therapy

Publication Name: Medical oncology (Northwood, London, England)
Publication Date: 2025-07-19
DOI: 10.1007/s12032-025-02870-7

Motixafortide acetate

Publication Name: Pharmaceutical Substances
Publication Date: 2025

Peptidomimetic inhibitors of the VEGF-A165/NRP-1 complex obtained by modification of the C-terminal arginine

Publication Name: Amino Acids
Publication Date: 2024-08-24
DOI: 10.1007/s00726-024-03411-8

Histone Protein Epitope Mapping for Autoantibody Recognition in Rheumatoid Arthritis.

Publication Name: Methods in Molecular Biology
Publication Date: 2018-12-12
DOI: 10.1007/978-1-4939-8949-2_18